Efficacy and safety of antiviral treatment on blocking the mother‐to‐child transmission of hepatitis B virus: A meta‐analysis
Authors:
- 11 November 2018
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 26 (3) , 397-406
Abstract
Summary: Nucleo(t)side analogues (NAs) have been administered as adjunctive therapy to interrupt the mother‐to‐child transmission (MTCT) of hepatitis B virus (HBV). The efficacy and safety of this method remain controversial. A meta‐analysis was conducted to evaluate the efficacy and safety of NAs treatment during pregnancy. The differences among different agents and initiation trimesters were analysed. A total of 9228 mother‐infant pairs in 59 studies (32 RCTs and 27 non‐RCTs) were included in this meta‐analysis. NAs significantly reduced the risk of MTCT, as indicated by seropositivity of hepatitis B surface antigen (HBsAg) (risk ratio (RR) = 0.51, 95% confidence interval (CI) 0.45‐0.57) and HBV DNA in newborns (RR = 0.22, 95% CI 0.18‐0.26). No differences in the efficacy of interrupting HBV MTCT were evident among lamivudine, telbivudine and tenofovir disoproxil fumarate. NA was more effective when administered from the second than from the third trimester as indicated by HBV DNA (RR: the second vs the third 0.08 vs 0.22, P = 0.010), but this effect was not evident as indicated by HBsAg (RR: the second vs the third 0.46 vs 0.53, P = 0.596). Antiviral treatment initiated from the second trimester did not confer a higher risk of safety problems in the newborns compared with treatment from the third trimester, as indicated by weight (P = 0.064), length (P = 0.491) and malformation rate (P = 0.635) of newborns.Conclusions: Lamivudine, telbivudine and tenofovir disoproxil fumarate are equally effective in blocking HBV MTCT. Antiviral treatment can be applied from the second trimester, without obvious safety concerns.Keywords
This publication has 36 references indexed in Scilit:
- Medical Virology of Hepatitis B: how it began and where we are nowVirology Journal, 2013
- Effect of diammonium glycyrrhizinate on entecavir pharmacokinetics in ratsChinese Journal of Natural Medicines, 2013
- The efficacy and safety of antiviral therapy with lamivudine to stop the vertical transmission of hepatitis B virusEuropean Journal of Clinical Microbiology & Infectious Diseases, 2012
- A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infectionJournal of Hepatology, 2011
- A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virusWorld Journal of Gastroenterology, 2011
- Management of Chronic Hepatitis B in PregnancyClinics in Liver Disease, 2010
- Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double‐blind, placebo‐controlled studyJournal of Viral Hepatitis, 2009
- Antiviral drug-resistant HBVHepatology, 2007
- Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infectionJournal of Viral Hepatitis, 2003
- Adefovir dipivoxil safety and pharmacokinetics in subjects with hepatitis B virus infection and in healthy subjectsJournal of Hepatology, 2002